In this issue of Blood, five satellite manuscripts from the Functional Annotation of the Mammalian Genome (FANTOM5) consortium show the power of deep transcriptome sequencing to identify genes, promoters, and enhancers specific to different hematopoietic subpopulations. [1] [2] [3] [4] [5] The papers by Motakis et al 1 T he FANTOM5 consortium consisting of .250 researchers from 20 countries and coordinated at RIKEN Yokohama, Japan, has used cap analysis of gene expression (CAGE) to map transcription start sites and generate a comprehensive expression atlas across a collection of 975 human and 399 mouse samples. 6 Of particular interest to Blood readers, primary cells covering the majority of hematopoietic lineages have been profiled. Additionally, 50 different blood cancer-derived cell lines were included, providing a rich data source for comparison between normal and disease states. The atlas provides expression profiles for known and novel, and coding and noncoding transcripts alike, and as revealed below, even identifies active enhancer elements.
A particular highlight of the Blood papers is the analyses on enhancers. One outcome of the FANTOM5 project was the realization that active enhancers could be mapped based on the observation that they generate CAGE tags in both directions. 7 With such a map of active enhancers, 3 of the Blood papers, Rönnerblad et al 3 and the 2 papers by Schmidl et al, 4, 5 are able to examine for the first time lineagespecific differences at these active enhancers.
Rönnerblad et al 3 combine DNA methylome profiles with CAGE and microarray expression profiles to examine changes during granulopoiesis. The authors conclude that the differentially methylated sites are preferentially located in areas distal to CpG islands and shores and enriched at enhancer elements that become active during differentiation.
The first paper by Schmidl et al 5 examines differences between human monocyte subsets: classical (CD14 11 CD16 2 ), intermediate (CD14 1 CD16 1 ), and nonclassical (CD14dimCD16 1 ). Using a combination of CAGE and genome-wide chromatin immunoprecipitation data (ChIP-seq) for histone modifications associated with enhancers, the authors examine the landscape of transcripts (coding, and noncoding) and transcribed enhancers used in each monocyte population. Nonclassical monocytes appear to have higher oxidative and mitochondrial activities and interestingly express higher levels of the interferon induced transmembrane proteins (IFITM1, IFITM2, and IFITM3), all linked to viral resistance. 8 Similarly in the second paper by Schmidl et al, 4 naïve and memory conventional and regulatory T cells are profiled by CAGE and ChIP-seq. The enhancer-specific marks were also tested here, but this time the authors examine the genome-wide binding of the transcription factors forkhead box P3 (FOXP3), runt-related transcription factor 1 (RUNX1), v-ets avian erythroblastosis virus E26 oncogene homolog 1 (ETS1), and signal transducer and activator of transcription 5B (STAT5). They find that STAT5 was enriched at enhancers active in regulatory T cells, whereas RUNX1 and ETS1 were enriched at conventional T-cell enhancers. Surprisingly FOXP3, the key determinant of regulatory T cells, was at enhancers of both regulatory and conventional T cells.
By profiling freshly isolated skin mast cells and expanded and stimulated mast cells, Motakis et al challenge 2 commonly held theories. 1 The data suggest that native mast cells and basophils are more distantly related than previously thought and that they express significantly fewer typical immune-related genes than previous reports suggest. The data also find a diverse collection of proteins previously not associated with mast cell function, including functional bone morphogenetic protein receptors. The authors demonstrate bone morphogenetic proteins promote survival of mast cells.
Last, Prasad et al 2 overviews the expression of 199 epigenetic regulators in hematopoiesis. The work is the first of its kind and identifies epigenetic regulators specific to different blood lineages and with enriched expression in leukemia lines. Of note, the authors identify factors previously implicated in leukemia (lysine [K]-specific methyltransferase 2A [KMT2A], chromobox homolog 8 [CBX8], and enhancer of polycomb homolog 1 [EPC1]).
Together, these 5 papers highlight the power of deep transcriptome profiling in isolated primary cell populations in the context of a large comparative atlas. Further studies on rarer populations will follow in the months to come. On a final note, genomewide analyses of cell type-specific transcripts revealed that a large fraction of the mammalian genome is specifically expressed in the hematopoietic lineages, the majority of which appear to be previously unrecognized transcripts including novel long noncoding and enhancer RNAs. 6 Additionally, an evolutionary study of protein domain architectures points to early evolution of myeloid and later evolution of lymphoid (in particular, T) cells. 9 There is much more to find in the FANTOM5 data.
Conflict-of-interest disclosure: The author declares no competing financial interests. n A half-century ago, Warburg postulated that mitochondrial respiration is impaired in cancer cells and the failure of adenosine triphosphate (ATP) production by mitochondria is compensated by an increased anaerobic glycolysis. 2 Although this theory has been confirmed in many solid tumors, less is understood about the metabolism of leukemic cells. It was demonstrated that chronic lymphocytic leukemia (CLL) cells have increased mitochondrial biogenesis 3 and ROS production compared with normal B cells and that high levels of ROS have been detected in more aggressive CLL cells. 4 However, the source of ROS production in CLL cells and whether the oxidative stress could affect immune function of the T cell are not clear. In this issue, Jitschin et al present evidence that (CLL) cells have elevated mitochondrial oxidative phosphorylation but do not have increased aerobic glycolysis, demonstrating that circulating CLL cells and solid tumor cells rely on distinct bioenergetics. 1 Importantly, the greater mitochondrial respiration leads to increased ROS production and intrinsic oxidative stress.
First, the authors determined the status of oxidative stress in the sera from 63 CLL patients compared with healthy donors. DNA-(8-OHdG) and lipid oxidation (malondialdehyde [MDA]) were used as surrogate markers for ROS. They found that CLL cells have significantly increased levels of both 8-OHdG and MDA. Higher levels of ROS correlated with numbers of circulating CLL cells. Immune cells are sensitive to ROS-induced damage or even cell death by apoptosis. Increased levels of ROS in the microenvironment can be detrimental for immune cells. Our previous study demonstrated that CD4 1 and CD8 1 T cells in CLL show impaired immunologic synapse formation. 5 Jitschin et al detected that CD4 1 and CD8 1 T cells in ROS high patients showed significantly reduced levels of CD3z chain expression. Particularly, ROS high patients have less activated phenotype of CD4 1 cells. The addition of the antioxidant N-acetyl-cysteine (NAC) prevented CLL cell-mediated T-cell dysfunction.
Intracellular ROS are often generated via the catalytic action of NADHP oxidase (NOX) and/or the mitochondrial electron transport chain (mETC) which is cell type-dependent. The authors found that CLL cells have lower expression of gp91, a subunit of NOX, compared with normal B cells. CLL and normal B cells showed a similar capacity in responding to stimulation of NOX by either an increase in its substrate or induction of respiratory burst by phorbol 12-myristate 13-acetate, indicating that NOX is not responsible for ROS overproduction by CLL cells. Gene expression of intracellular antioxidants catalase and heme oxygenase-1 (HO-1) was significantly increased in CLL cells. By contrast, mitochondrial manganese superoxide dismutase (MnSOD) expression was significantly reduced in CLL cells. Jitschin and colleagues suggested that significantly increased mitochondrial superoxide production might be caused, at least in part, by reduced levels of MnSOD. To further identify the ROS generation system in CLL cells, the mitochondrial targeting antioxidant MitoQ and NOX inhibitor diphenyleneiodonium were used to inhibit ROS production. Only MitoQ led to a significant reduction of ROS production, indicating that mitochondria are the source of ROS production in CLL cells.
Using multiple techniques, the authors thoroughly demonstrate that CLL cells have an increased mitochondrial biogenesis, such as increased mitochondrial mass, membrane potential, ATP production, mitochondrial DNA copy numbers, oxygen consumption, and mETC activity. Mitochondrial transcription factor (TFAM) is highly expressed in CLL cells and this may lead to an increased mitochondrial mass. However, aerobic glycolysis is not increased in CLL cells compared with normal B cells. This supports
